1. Психические расстройства и расстройства поведения (F00 - F99). Класс V МКБ-10, адаптированный для использования в Российской Федерации. Под общей редакцией Казаковцева Б.А., Голланда В.Б. - М.: Минздрав России, 1998. - 512 с.

2. O"Donovan MC; Williams N.M., Owen M.J. Recent advances in the genetics of schizophrenia.//Human Molecular Genetics. 2003, 12 (2): 125 - 133. doi:10.1093/hmg/ddg302

3. Nagel M, Jansen PR, Stringer S, Watanabe K, de Leeuw CA, Bryois J, Savage JE, Hammerschlag AR, Skene NG, AB; 23andMe Research Team, White T, Tiemeier H, Linnarsson S, Hjerling-Leffler J, Polderman TJC, Sullivan PF, van der Sluis S, Posthuma D. Meta-analysis of genome-wide association studies for neuroticism in 449, 484 individuals identifies novel genetic loci and pathways. Nat Genet. 2018 50(7): 920 - 927. doi: 10.1038/s41588-018-0151-7

4. Rasic D, Hajek T, Alda M, Uher R. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies. Schizophr Bull. 2014 Jan; 40(1): 28 - 38. doi: 10.1093/schbul/sbt114.

5. Стал С.М. Основы психофармакологии. Теория и практика. М.: ГЭОТАР-Медиа, 2020. - 656 с.

6. Green M.F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. Journal of Clinical Psychiatry 2006. 67(9): 3 - 8.

7. Molina V., Sanz J., Reig S., R., Sarramea F., Luque R. et al. Hypofrontality in men with first-episode psychosis. British Journal of Psychiatry 2005. 186: 203 - 208. - doi: 10.1192/bjp.186.3.203

8. Модели безумия: Психологические, социальные и биологические подходы к пониманию шизофрении. Под ред. Дж. Рида, Л.Р. Мошера, Р.П. Бенталла. - Ставрополь: Возрождение, 2008. - 412 с.

9. Mueser K.T., McGurk S.R. Schizophrenia. The Lancet. 2004, 363 (9426): 2063 - 2072. doi: 10.1016/S0140-6736(04)16458-1

10. Fraguas D, CM, Ayora M, F, A, Recio S, Leza JC, Arango C. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. Schizophr Bull. 2019 45(4): 742 - 751. doi: 10.1093/schbul/sby125.

11. Salamon S, Santelmann H, Franklin J, Baethge C. Test-retest reliability of the diagnosis of schizoaffective disorder in childhood and adolescence - A systematic review and meta-analysis. J Affect Disord. 2018. 230: 28 - 33. doi: 10.1016/j.jad.2017.12.070.

12. Os J., Kapur S. Schizophrenia. Lancet. 2009, 374 (9690): 635 - 645. DOI: https://doi.org/10.1016/S0140-6736(09)60995-8

13. Picchioni M.M., Murray R.M. Schizophrenia. BMJ. 2007, 335(7610): 91 - 95. DOI: 10.1136/bmj.39227.616447.BE

14. Clemmensen L., Vernal D. L., Steinhausen H. C. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012, 12: 150 - 156. doi: 10.1186/1471-244X-12-150

15. Ishal Madaan, Yael Dvir, Daniel R Wilson. Child and adolescent schizophrenia: pharmacological approaches. Informa Healthcare. 2008, 9, (12): 2053 - 2068. doi:10.1517/14656566.9.12.2053

16. Ремшмидт Х. Детская и подростковая психиатрия: Введение в практику. М.: ЭКСМО-Пресс, 2001. 624 с.

17. Демчева Н.К., Пронина Л.А., Положая З.Б. Показатели инвалидности детей по психическому заболеванию в Российской Федерации в 2002 - 2012 гг. Вестник неврологии, психиатрии и нейрохирургии. 2014, 1: 3 - 11

18. Макушкин Е.В., Демчева Н.К. Динамика и сравнительный анализ детской и подростковой заболеваемости психическими расстройствами в Российской Федерации в 2000 - 2018 годах. Российский психиатрический журнал. 2019, 4: 4 - 15.

19. Robert L. Spitzer, Dennis P. Cantwell. The DSM-III Classification of the Psychiatric Disorders of Infancy, Childhood, and Adolescence Journal of the American Academy of Child and Adolescent Psychiatry (англ.) Elsevier BV, 1980, 19 (3): 356 - 370. doi: 10.1016/s0002-7138(09)61059-1

20. Психические расстройства и расстройства поведения (F00 - F99). Класс V МКБ-10, адаптированный для использования в Российской Федерации. Под общей редакцией Казаковцева Б.А., Голланда В.Б. - М.: Минздрав России, 1998. - 512 с.

21. Психические расстройства и расстройства поведения (F00 - F99). Класс V МКБ-10, адаптированный для использования в Российской Федерации. Под общей редакцией Казаковцева Б.А., Голланда В.Б. - М.: Минздрав России, 1998. - 512 с.

22. Шизофрения: Мультидисциплинарное исследование/Под ред. А.В. Снежневского; Акад. мед. наук. - Москва: Медицина, 1972. - 400 с

23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). - Arlington, VA: American Psychiatric Publishing, 2013. - 992 p

24. Психические расстройства и расстройства поведения (F00 - F99). Класс V МКБ-10, адаптированный для использования в Российской Федерации. Под общей редакцией Казаковцева Б.А., Голланда В.Б. - М.: Минздрав России, 1998. - 512 с.

25. Башина В.М., Симашкова Н.В. Систематика детской шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова 1989. 89(8): 69 - 75

26. Ambrosini PJ. Historical developments and present status of the schedule for affective disorders and schizophrenia for school age children (K-SADS). J Am Acad Child Adolesc Psychiatry 39: 49 - 58, 2000

27. Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M: Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 42(9): 1857 - 1863, 2012

28. Kaplan and Sadock's handbook of clinical psychiatry. Philadelphia, Williams&Wilkins, 2001. 480 p.

29. Hollis C: Child and adolescent (juvenile onset) schizophrenia. A case control study of premorbid developmental impairments. Br J Psychiatry 166(4): 489 - 495, 1995

30. Laurens KR, Luo L, Matheson SL, et al.: Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. BMC Psychiatry 15: 205, 2015

31. Schaeffer JL, Ross RG: Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry 41(5): 538 - 545, 2002

32. Lewis SW, Murray RM: Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia. J Psychiatr Res 21(4): 413 - 421, 1987

33. Ремшмидт Х. Детская и подростковая психиатрия: Введение в практику. М.: ЭКСМО-Пресс, 2001. 624 с.

34. Психиатрия: национальное руководство. М.: ГЭОТАР-Медиа, 2018. 1008 с.

35. Weissman MM, Wickramaratne P, Warner V, et al.: Assessing psychiatric disorders in children: discrepancies between mothers' and children's reports. Arch Gen Psychiatry 44: 747 - 753, 1987

36. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H: Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 57(11): 1053 - 1058, 2000

37. Dhossche D, Ferdinand R, Van der Ende J, Hofstra MB, Verhulst F: Diagnostic outcome of self-reported hallucinations in a community sample of adolescents. Psychol Med 32(4): 619 - 627, 2002

38. Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M: Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 42(9): 1857 - 1863, 2012

39. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L: A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 39(2): 179 - 195, 2009

40. Driver DI, Gogtay N, Rapoport JL: Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am 22(4): 539 - 555, 2013

41. Психиатрия: национальное руководство. М.: ГЭОТАР-Медиа, 2018. 1008 с.

42. Glasner-Edwards S, Mooney L. J. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014. 28(12): 1115 - 26. doi: 10.1007/s40263-014-0209-8.

43. Rosenthal R.N, Miner C.R. Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorders. Schizophr Bull. 1997; 23(2): 187 - 93. doi: 10.1093/schbul/23.2.187

44. Фастовцов Г.А., Осколкова С.Н. Проблема диагностики шизофрении у больных, употребляющих психоактивные вещества. Российский психиатрический журнал. 2018. 5: 51 - 63

45. Менделевич В.Д. Психотические расстройства вследствие употребления наркотиков. Наркология. 2014. 7: 93 - 100

46. Rimvall M.K, Jespersen C.P, Clemmensen L, Munkholm A, Skovgaard A.M, Verhulst F, van Os J, Rask C.U, Jeppesen P. Psychotic experiences are associated with health anxiety and functional somatic symptoms in preadolescence. J Child Psychol Psychiatry. 2019. 60(5): 524 - 532. doi: 10.1111/jcpp.12986.

47. Frajerman A, Morin V, Chaumette B, Kebir O, Krebs M.O Management of cardiovascular co-morbidities in young patients with early onset psychosis: State of the art and therapeutic perspectives. Encephale. 2020. 46(5): 390 - 398. doi: 10.1016/j.encep.2020.03.007

48. Godbout R. Treatment of sleep disorders in children with a psychiatric diagnosis. Sante Ment Que. 2015. 40(2): 257 - 74

49. Bray T, Agius M. Soft neurological signs and schizophrenia - a looking glass into core pathology? Psychiatr Danub. 2009. 21(3): 327 - 8.

50. Vonberg F.W, Bigdeli T.B. Genetic Correlation Between Schizophrenia and Epilepsy. JAMA Neurol. 2016. 73(1): 125 - 6. doi: 10.1001/jamaneurol.2015.3480.

51. Brown AS, Gyllenberg D, S, Sourander A, McKeague IW. Altered growth trajectory of head circumference during infancy and schizophrenia in a National Birth Cohort. Schizophr Res. 2017. 182: 115 - 119. doi: 10.1016/j.schres.2016.10.032.

52. McCauley E, Carlson G.A, Calderon R. The role of somatic complaints in the diagnosis of depression in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1991. 30(4): 631 - 5. doi: 10.1097/00004583-199107000-00016.

53. Lukkari S, Hakko H, Taanila A, P, Riala K, Herva A. Body size at birth and psychiatric disorders among adolescents: a clinical study of 310 under-age inpatient adolescents in Northern Finland. Compr Psychiatry. 2014. 55(3): 414 - 21. doi: 10.1016/j.comppsych.2013.10.005.

54. Sormunen E, Saarinen MM, Salokangas RKR, Telama R, N, Tammelin T, Viikari J, Raitakari O, Hietala J. Effects of childhood and adolescence physical activity patterns on psychosis risk-a general population cohort study. NPJ Schizophr. 2017. 13: 3 - 5. doi: 10.1038/s41537-016-0007-z.

55. Druyts E, Eapen S, Wu P, Thorlund K. The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis. Syst Rev. 2014. 13; 3: 116. doi: 10.1186/2046-4053-3-116

56. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011 1; 34(8): 651 - 68. doi: 10.2165/11592020-000000000-00000

57. Vonberg FW, Bigdeli TB. Genetic Correlation Between Schizophrenia and Epilepsy. JAMA Neurol. 2016. 73(1): 125 - 6. doi: 10.1001/jamaneurol.2015.3480.

58. Ritvo E.R, Ornitz E.M, Walter R.D, Hanley J. Correlation of psychiatric diagnoses and EEG findings: a double-blind study of 184 hospitalized children. Am J Psychiatry. 1970 126(7): 988 - 96. doi: 10.1176/ajp.126.7.988.

59. Levman J, Takahashi E. Multivariate analyses applied to fetal, neonatal and pediatric MRI of neurodevelopmental disorders. Neuroimage Clin. 2015 3; 9: 532 - 44. doi: 10.1016/j.nicl.2015.09.017.

60. Park MTM, Raznahan A, Shaw P, Gogtay N, Lerch JP, Chakravarty MM. Neuroanatomical phenotypes in mental illness: identifying convergent and divergent cortical phenotypes across autism, ADHD and schizophrenia. J Psychiatry Neurosci. 2018. 43(3): 201 - 212. doi: 10.1503/jpn.170094.

61. Correll CU, Harris J, Figen V, Kane JM, Manu P. Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. J Child Adolesc Psychopharmacol. 2011. 21(4): 365 - 8. doi: 10.1089/cap.2011.0024.

62. Jensen KG, S, Correll CU, D, Klauber DG, Stentebjerg-Olesen M, Fagerlund B, Jepsen JR, Fink-Jensen A, Juul K, Pagsberg AK. Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. Psychopharmacology 2018. 235(3): 681 - 693. doi: 10.1007/s00213-017-4784-5.

63. Ho J.G, Caldwell R.L, McDougle C.J, Orsagh-Yentis D.K, Erickson C.A, Posey D.J, Stigler K.A The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2012 22(4): 277 - 83. doi: 10.1089/cap.2011.0129.

64. DelBello M.P, Versavel M, Ice K, Keller D, Miceli J. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol. 2008. 18(5): 491 - 9. doi: 10.1089/cap.2008.008

65. van Erp T.G.M, Walton E, Hibar D.P, Schmaal L, Jiang W et all. White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individuals. Mol Psychiatry. 2020 25(4): 883 - 895. doi: 10.1038/s41380-019-0553-7.

66. Walton E, Hibar D.P, van Erp T.G.M, Potkin S.G, R et all. Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium. Psychol Med. 2018. 48(1): 82 - 94. doi: 10.1017/S0033291717001283.

67. Dezhina Z, Ranlund S, Kyriakopoulos M, Williams SCR, Dima D. A systematic review of associations between functional MRI activity and polygenic risk for schizophrenia and bipolar disorder. Brain Imaging Behav. 2019. 13(3): 862 - 877. doi: 10.1007/s11682-018-9879-z.

68. Зверева Н.В., Хромов А.И., Сергиенко А.А., Коваль-Зайцев А.А. Клинико-психологические методики оценки когнитивного развития детей и подростков при эндогенной психической патологии (память и мышление). М.: "Сам полиграфист", 2017. - 48 с.

69. Зверева Н.В., Коваль-Зайцев А.А., Хромов А.И. Патопсихологические методики оценки когнитивного развития детей и подростков при эндогенной психической патологии (зрительное восприятие и мышление). М.: "Издательство МБА", 2014. - 40 с.

70. Pagsberg A.K, Tarp S, Glintborg D, A.D, Fink-Jensen A, Correll C.U, Christensen R. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017. 56(3): 191 - 202. doi: 10.1016/j.jaac.2016.12.013

71. Harvey R.C, James A.C, Shields G.E. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs. 2016. 30(1): 27 - 39. doi: 10.1007/s40263-015-0308-1

72. S.D, Foldager L, Mors O, Bech P, Correll C.U. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Acta Psychiatr Scand. 2018. 138(5): 420 - 431. doi: 10.1111/acps.12952

73. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R.R. What does the PANSS mean? Schizophr Res. 2005.15; 79(2 - 3): 231 - 8. doi: 10.1016/j.schres.2005.04.008.

74. SD, Foldager L, Mors O, Bech P, Correll C.U. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. Schizophr Bull. 2018 15; 44(2): 453 - 462. doi: 10.1093/schbul/sbx076

75. Мосолов С.Н. Шкалы психометрической оценки симптоматики шизофрении и концепция позитивных и негативных расстройств. М, 2001. 238 с.

76. Opler L.A., Kay S.R., Lindenmayer J.P., Fiszbein A. Structured Clinical Interview Positive and Negative Syndrome Scale (SCI-PANSS).//Multi-Health Systems Inc., Toronto, 1999, N 4, 15 p.

77. Fields J. H. et al. A POSITIVE AND NEGATIVE SYMPTOM SCALE FOR CHILDREN AND ADOLESCENTS: THE KIDDIE-PANSS//Clinical Neuropharmacology. - 1992. - Т. 15. - С. 52B.

78. D Schaub, G Juckel PSP Scale: German version of the Personal and Social Performance Scale: valid instrument for the assessment of psychosocial functioning in the treatment of schizophrenia Nervenarzt. 2011. 82(9): 1178 - 84. doi: 10.1007/s00115-010-3204-4

79. Juckel, G., & Morosini, P. L. The new approach: Psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Current Opinion in Psychiatry, 2008. 21, 630 - 639

80. Juckel, G., Schaub, D., Fuchs, N., Naumann, U., Uhl, I., Witthaus, H., Hargarter, L., Bierhoff, H.-W., & , M. Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophrenia Research, 2008. 104(1-3): 287 - 293

81. Morosini P.L, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica 2000. 101: 323 - 329.

82. Tianmei S, Liang S, Yun"ai S, Chenghua T, Jun Y, Jia C, Xueni L, Qi L, Yantao M, Weihua Z, Hongyan Z. The Chinese version of the Personal and Social Performance Scale (PSP): validity and reliability. Psychiatry Res. 2011. 30; 185(1-2): 275 - 9. doi: 10.1016/j.psychres.2010.05.001

83. Стал С.М. Основы психофармакологии. Теория и практика. М.: ГЭОТАР-Медиа, 2020. - 656 с.

84. Мосолов С.Н., Цукарзи Э.Э. Психофармакотерапия шизофрении//Психиатрия: национальное руководство/под ред. Н.Г. Незнанова, Ю.А. Александровского. М.: Гэотар-медиа, 2018. С. 299 - 328

85. Мосолов С.Н. Основы психофармакотерапии. - М.: Восток, 1996. - 288 с.

86. Zimmermann G., Favrod J., Trieu V.H., Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophrenia Research. 2005. 77(1): 1 - 9.

87. Нельсон А.И. Электросудорожная терапия в психиатрии, наркологии и неврологии М: БИНОМ. Лаборатория знаний. 2005. - 368 с.

88. Geretsegger C. Electroconvulsive therapy (ECT). Fortschr Neurol Psychiatr. 1986. 54(5): 139 - 53. doi: 10.1055/s-2007-1001859.

89. Tharyan, P. Adams, C.E. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2005. No. 2. P. CD000076. - doi: 10.1002/14651858.CD000076.pub2

90. Greenhalgh J. et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies//Health Technology Assessment (Winchester, England). - 2005. - Т. 9. - N. 9. - С. 1 - 156

91. Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Am J Psychiatry. 2020. 177(4): 342 - 353. doi: 10.1176/appi.ajp.2019.19010034

92. Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev. 2007. 18(3): CD004027. doi: 10.1002/14651858.CD004027.pub2

93. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, Leucht S. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol. 2018. 28(6): 659 - 674. doi: 10.1016/j.euroneuro.2018.03.008

94. Harvey RC, James AC, Shields GE. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs. 2016. 30(1): 27 - 39. doi: 10.1007/s40263-015-0308-1.

95. Abidi S, Mian I, Garcia-Ortega I, Lecomte T, Raedler T, Jackson K, Jackson K, Pringsheim T, Addington D. Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth. Can J Psychiatry. 2017. 62(9): 635 - 647. doi: 10.1177/0706743717720197.

96. Pringsheim T. et al. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth//Paediatrics & child health. - 2011. - Т. 16. - N. 9. - С. 590 - 598.

97. Harvey RC, James AC, Shields GE. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs. 2016. 30(1): 27 - 39. doi: 10.1007/s40263-015-0308-1

98. Pine DS, Cohen E. Therapeutics of aggression in children. Paediatr Drugs. 1999. 1(3): 183 - 96. doi: 10.2165/00128072-199901030-00003

99. Saha KB, Bo L, Zhao S, Xia J, Sampson S, Zaman RU. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2016. 4(4): CD010631. doi: 10.1002/14651858.CD010631.pub2

100. Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS. Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev. 2013. (10): CD009582. doi: 10.1002/14651858.CD009582.pub2

101. Sarkar S, Grover S. Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis. Indian J Pharmacol. 2013. 45(5): 439 - 46. doi: 10.4103/0253-7613.117720

102. Xia L, Li WZ, Liu HZ, Hao R, Zhang XY. Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials. J Child Adolesc Psychopharmacol. 2018. 28(4): 244 - 251. doi: 10.1089/cap.2017.0120

103. Авруцкий Г.Я., Недува А.А. Лечение психически больных. - 2-е изд. - М.: Медицина, 1988. - 528 с.

104. Green W. H. et al. Schizophrenia with childhood onset: a phenomenological study of 38 cases//Journal of the American Academy of Child & Adolescent Psychiatry. - 1992. - Т. 31. - N. 5. - С. 968 - 976.

105. Alderton H. R., Hoddinott B. A. A controlled study of the use of thioridazine in the treatment of hyperactive and aggressive children in a children"s psychiatric hospital//Canadian Psychiatric Association Journal. - 1964. - Т. 9. - N. 3. - С. 239 - 247.

106. Мосолов С.Н. Основы психофармакотерапии. - М.: Восток, 1996. - 288 с.

107. Bachmann C. J. et al. Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012//Deutsches International. - 2014. - Т. 111. - N. 3. - С. 25.

108. Remschmidt H. E. et al. Childhood-onset schizophrenia: history of the concept and recent studies//Schizophrenia bulletin. - 1994. - Т. 20. - N. 4. - С. 727 - 745.

109. Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry. 1998. 59(12): 644 - 56. doi: 10.4088/jcp.v59n1202

110. Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleischhacker WW, B, Leboyer M, Leweke FM, Lewis S, McGuire P, Meyer-Lindenberg A, Rujescu D, Kapur S, Kahn RS, Sommer IE. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015. 41(3): 549 - 58. doi: 10.1093/schbul/sbv019.

111. Wang J, Sampson S. Sulpiride versus placebo for schizophrenia. Cochrane database Syst Rev. 2014; (4): CD007811. doi: 10.1002/14651858.CD007811.pub2

112. Omori IM, Wang J. Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev. 2009. 15; (2): CD007811. doi: 10.1002/14651858.CD007811

113. Bachmann C. J. et al. Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012//Deutsches International. - 2014. - Т. 111. - N. 3. - С. 25

114. Hosam E Matar, Muhammad Qutayba Almerie, Samer Makhoul, Jun Xia, Pamela Humphreys Pericyazine for schizophrenia Cochrane Database Syst Rev. (5): CD007479. doi: 10.1002/14651858.CD007479.pub2.

115. Личко А.Е. Шизофрения у подростков. Л.: Медицина: Ленингр. отд-ние, 1989. - 214 с.

116. Flank J, Sung L, Dvorak CC, Spettigue W, Dupuis LL. The safety of olanzapine in young children: a systematic review and meta-analysis. Drug Saf. 2014. 37(10): 791 - 804. doi: 10.1007/s40264-014-0219-y

117. Pagsberg AK, Tarp S, Glintborg D, AD, Fink-Jensen A, Correll CU, Christensen R. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017. 56(3): 191 - 202. doi: 10.1016/j.jaac.2016.12.013

118. Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Psychopharmacol Bull. 2010; 43(2): 45 - 66.

119. Sarkar S, Grover S. Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis. Indian J Pharmacol. 2013 45(5): 439 - 46. doi: 10.4103/0253-7613.117720

120. Armenteros JL, Davies M. Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2006. (3): 141 - 8. doi: 10.1007/s00787-005-0515-2.

121. Pagsberg AK, Tarp S, Glintborg D, AD, Fink-Jensen A, Correll CU, Christensen R. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017 56(3): 191 - 202. doi: 10.1016/j.jaac.2016.12.013

122. Harvey RC, James AC, Shields GE. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs. 2016. 30(1): 27 - 39. doi: 10.1007/s40263-015-0308-1

123. Pagsberg AK, Tarp S, Glintborg D, AD, Fink-Jensen A, Correll CU, Christensen R. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017 56(3): 191 - 202. doi: 10.1016/j.jaac.2016.12.013

124. Gentile S. Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders. Paediatr Drugs. 2011. 13(5): 291 - 302. doi: 10.2165/11591250-000000000-00000

125. Pagsberg A. K. et al. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial//The Lancet Psychiatry. - 2017. - Т. 4. - N. 8. - С. 605 - 618.

126. Lerner V. Biperiden (Akineton): a literature review. Psychiatry and Psychopharmacotherapy, 2014. 10: 36 - 43

127. Маслеников Н.В., Цукарзи Э.Э., Мосолов С.Н. Алгоритм биологической терапии депрессии при шизофрении. Современная терапия психических расстройств. 2019. 1: 31 - 39

128. Мосолов С.Н. Клиническое применение современных антидепрессантов. СП., "Медицинское информационное агентство", 1995. - 568 с.

129. Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, 53 substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015. 16 (3): 142 - 170

130. Jerrell J. M., McIntyre R. S., Deroche C. B. Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia//Human Psychopharmacology: Clinical and Experimental. - 2017. - Т. 32. - N. 2. - С. e2585.

131. Kang-Yi C. D. et al. Psychiatric Diagnoses and Treatment Preceding Schizophrenia in Adolescents Aged 9 - 17 Years//Frontiers in Psychiatry. - 2020. - Т. 11. - С. 487.

132. Coskun M., Zoroglu S. Clozapine induced obsessions treated with sertraline in an adolescent with schizophrenia//Klinik Psikofarmakoloji Bulteni. - 2009. - Т. 19. - N. 2. - С. 155

133. Jerath A. U., Mavrides N. A., Coffey B. J. Complexity in Evaluation and Pharmacological Treatment of Early Onset Psychosis with Mood Symptoms: Childhood Onset Schizophrenia or Affective Disorder?//Journal of child and adolescent psychopharmacology. - 2019. - Т. 29. - N. 3. - С. 241 - 244

134. Jerrell J. M., McIntyre R. S., Deroche C. B. Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia//Human Psychopharmacology: Clinical and Experimental. - 2017. - Т. 32. - N. 2. - С. e2585.

135. Kang-Yi C. D. et al. Psychiatric Diagnoses and Treatment Preceding Schizophrenia in Adolescents Aged 9 - 17 Years//Frontiers in Psychiatry. - 2020. - Т. 11. - С. 487.

136. Abidi, S., Mian, I., Garcia-Ortega, I., Lecomte, T., Raedler, T., Jackson, K., Jackson, K., Pringsheim, T., & Addington, D. Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth. Canadian journal of psychiatry. 2017. 62(9): 635 - 647. https://doi.org/10.1177/0706743717720197

137. Huband N, Ferriter M, Nathan R, Jones H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev. 2010. 2010(2): CD003499. doi: 10.1002/14651858.CD003499.pub3

138. Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2012. 14; 11(11): CD006391. doi: 10.1002/14651858.CD006391.pub2

139. Дедкова А.Е. Опыт эффективного применения бензодиазепинов при кататонии, осложненной злокачественным нейролептическим синдромом. Современная терапия психических расстройств 2016. 2: 29 - 34.

140. Benarous X, Raffin M, Ferrafiat V, Consoli A, Cohen D. Catatonia in children and adolescents: New perspectives. Schizophr Res. 2018. 200: 56 - 67. doi: 10.1016

141. Sidorchuk A. et al. Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study//PLoS medicine. - 2018. - Т. 15. - N. 8. - С. e1002635

142. Sevi Tok ES, Arkar H, Bildik T. The Effectiveness of Cognitive Behavioral Therapy, Medication, or Combined Treatment For Child Hood Anxiety Disorders. Turk Psikiyatri Derg. 2016 27(2): 10.

143. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010. 8; (12): CD000088. doi: 10.1002/14651858.CD000088.pub2.

144. Maurus I, A, Falkai P, Malchow B, Schmitt A, Hasan A. Nonpharmacological treatment of dyscognition in schizophrenia: effects of aerobic exercise. Dialogues Clin Neurosci. 2019. 21(3): 261 - 269. doi: 10.31887/DCNS.2019.21.3/aschmitt.

145. Broderick J, Crumlish N, Waugh A, Vancampfort D. Yoga versus non-standard care for schizophrenia. Cochrane Database Syst Rev. 2017 28; 9(9): CD012052. doi: 10.1002/14651858.CD012052.pub2.

146. Ruddy RA, Dent-Brown K. Drama therapy for schizophrenia or schizophrenia-like illnesses. Cochrane Database Syst Rev. 2007 24; (1): CD005378. doi: 10.1002/14651858.CD005378.pub2.

147. Valiente C, Espinosa R, Trucharte A, Nieto J, L. The challenge of well-being and quality of life: A meta-analysis of psychological interventions in schizophrenia. Schizophr Res. 2019. 208: 16 - 24. doi: 10.1016/j.schres.2019.01.040.

148. Laws KR, Darlington N, Kondel TK, McKenna PJ, Jauhar S. Cognitive Behavioural Therapy for schizophrenia - outcomes for functioning, distress and quality of life: a meta-analysis. BMC Psychol. 2018. 17; 6(1): 32. doi: 10.1186/s40359-018-0243-2.

149. Jones C, Hacker D, Xia J, Meaden A, Irving CB, Zhao S, Chen J, Shi C. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database Syst Rev. 2018. 20; 12(12): CD007964. doi: 10.1002/14651858.CD007964.pub2.

150. Ueland T., Rund B. R. A controlled randomized treatment study: the effects of a cognitive remediation program on adolescents with early onset psychosis//Acta Psychiatrica Scandinavica. - 2004. - Т. 109. - N. 1. - С. 70 - 74.

151. Ueland T, Rund BR. Cognitive remediation for adolescents with early onset psychosis: a 1-year follow-up study. Acta Psychiatr Scand 2005; 111: 193 - 201

152. van Oosterhout B, Smit F, Krabbendam L, Castelein S, Staring AB, van der Gaag M. Metacognitive training for schizophrenia spectrum patients: a meta-analysis on outcome studies. Psychol Med. 2016. 46(1): 47 - 57. doi: 10.1017/S0033291715001105.

153. Geretsegger M, KA, Bieleninik , Chen XJ, Heldal TO, Gold C. Music therapy for people with schizophrenia and schizophrenia-like disorders. Cochrane Database Syst Rev. 2017. 29; 5(5): CD004025. doi: 10.1002/14651858.CD004025.pub4

154. Gold C, Heldal TO, Dahle T, Wigram T. Music therapy for schizophrenia or schizophrenia-like illnesses. Cochrane Database Syst Rev. 2005. 18; (2): CD004025. doi: 10.1002/14651858.CD004025.pub2.

155. Potocky M. An art therapy group for clients with chronic schizophrenia//Social Work with Groups. - 1993. - Т. 16. - N. 3. - С. 73 - 82.

156. Izquierdo de Santiago A, Khan M. Hypnosis for schizophrenia. Cochrane Database Syst Rev. 2007. 17; 2007(4): CD004160. doi: 10.1002/14651858.CD004160.pub3

157. Gruzelier J. Unwanted effects of hypnosis: a review of the evidence and its implications//Contemporary Hypnosis. - 2000. - Т. 17. - N. 4. - С. 163 - 193

158. Психиатрия: Национальное руководство/Коллективная монография. Под ред. Александровского Ю.А., Незнанова Н.Г./- 2-е издание, переработанное и дополненное. Москва. 2018

159. Law E, Fisher E, Eccleston C, Palermo TM. Psychological interventions for parents of children and adolescents with chronic illness. Cochrane Database Syst Rev. 2019 18; 3(3): CD009660. doi: 10.1002/14651858.CD009660.pub4

160. Buckley LA, Maayan N, Soares-Weiser K, Adams CE. Supportive therapy for schizophrenia. Cochrane Database Syst Rev. 2015. 14; 2015(4): CD004716. doi: 10.1002/14651858.CD004716.pub4.

161. Gearing RE. Evidence-based family psychoeducational interventions for children and adolescents with psychotic disorders. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2008. 17(1): 2 - 11.

162. Куприянова Т.А., Корень Е.В. Программа (модуль) психосоциальной терапии для детей и подростков с расстройствами шизофренического спектра. Современная терапия психических расстройств. 2015. 3: 26 - 32.

163. Ueland T., Rund B. R. A controlled randomized treatment study: the effects of a cognitive remediation program on adolescents with early onset psychosis//Acta Psychiatrica Scandinavica. - 2004. - Т. 109. - N. 1. - С. 70 - 74.

164. Ueland T, Rund BR. Cognitive remediation for adolescents with early onset psychosis: a 1-year follow-up study. Acta Psychiatr Scand 2005; 111: 193 - 201

165. Cella M, Preti A, Edwards C, Dow T, Wykes T. Cognitive remediation for negative symptoms of schizophrenia: A network meta-analysis. Clin Psychol Rev. 2017. 52: 43 - 51. doi: 10.1016/j.cpr.2016.11.009.

166. Lewandowski KE. Cognitive Remediation for the Treatment of Cognitive Dysfunction in the Early Course of Psychosis. Harv Rev Psychiatry. 2016. 24(2): 164 - 72. doi: 10.1097/HRP.0000000000000108.

167. Bryce S, Sloan E, Lee S, Ponsford J, Rossell S. Cognitive remediation in schizophrenia: A methodological appraisal of systematic reviews and meta-analyses. J Psychiatr Res. 2016. 75: 91 - 106. doi: 10.1016/j.jpsychires.2016.01.004.

168. Wood L, Byrne R, Varese F, Morrison AP. Psychosocial interventions for internalised stigma in people with a schizophrenia-spectrum diagnosis: A systematic narrative synthesis and meta-analysis. Schizophr Res. 2016. 176(2-3): 291 - 303. doi: 10.1016/j.schres.2016.05.001.

169. Turner DT, McGlanaghy E, Cuijpers P, van der Gaag M, Karyotaki E, MacBeth A. A Meta-Analysis of Social Skills Training and Related Interventions for Psychosis. Schizophr Bull. 2018. 6; 44(3): 475 - 491. doi: 10.1093/schbul/sbx146

170. Kurtz MM, Richardson CL. Social cognitive training for schizophrenia: a meta-analytic investigation of controlled research. Schizophr Bull. 2012. 38(5): 1092 - 104. doi: 10.1093/schbul/sbr036.

171. Психиатрия: Национальное руководство/Коллективная монография. Под ред. Александровского Ю.А., Незнанова Н.Г./- 2-е издание, переработанное и дополненное. Москва. 2018

172. Shepherd TA, Ul-Haq Z, Ul-Haq M, Khan MF, Afridi A, Dikomitis L, Robinson ME, Lewis M, Rahman A, Dziedzic K, Saeed U, Awan NR, Mallen C, Farooq S. Supervised treatment in outpatients for schizophrenia plus (STOPS+): protocol for a cluster randomised trial of a community-based intervention to improve treatment adherence and reduce the treatment gap for schizophrenia in Pakistan. BMJ Open. 2020 30; 10(6): e034709. doi: 10.1136/bmjopen-2019-034709

173. Психиатрия: Национальное руководство/Коллективная монография. Под ред. Александровского Ю.А., Незнанова Н.Г./- 2-е издание, переработанное и дополненное. Москва. 2018

174. Lloyd A, Horan W, Borgaro SR, Stokes JM, Pogge DL, Harvey PD. Predictors of medication compliance after hospital discharge in adolescent psychiatric patients. J Child Adolesc Psychopharmacol. 1998; 8(2): 133 - 41. doi: 10.1089/cap.1998.8.133.

175. Краснов В.Н., Гурович И.Я., Мосолов С.Н., Шмуклер А.Б. с соавт. Психиатрическая помощь больным шизофренией. Клиническое руководство/Под редакцией В.Н. Краснова, И.Я. Гуровича, С.Н. Мосолова, А.Б. Шмуклера. Москва, 2007

176. Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthoj, Wagner F Gattaz, Florence Thibaut, . World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012. 13(5): 318 - 78. doi: 10.3109/15622975.2012.696143.

177. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. WFSBP Task force on Treatment Guidelines for Schizophrenia.World J Biol Psychiatry. 2013. 14(1): 2 - 44. doi: 10.3109/15622975.2012.739708.

178. Hasan A, Falkai P, Wobrock T, Lieberman J, B, Gattaz WF, Thibaut F, HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World J Biol Psychiatry. 2015. 16(3): 142 - 70. doi: 10.3109/15622975.2015.1009163

179. Макушкин Е.В., Симашкова Н.В., Горюнов А.В., Пережогин Л.О. Шизофрения в детском и подростковом возрасте//Российский психиатрический журнал. 2016. 6: 62 - 81.

180. Firth J, Cotter J, Elliott R, French P, Yung AR A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med. 2015; 45(7): 1343 - 61. doi: 10.1017/S0033291714003110.

181. Fusar-Poli P, Cappucciati M, Bonoldi I, Hui LM, Rutigliano G, Stahl DR, Borgwardt S, Politi P, Mishara AL, Lawrie SM, Carpenter WT Jr, McGuire PK. Prognosis of Brief Psychotic Episodes: A Meta-analysis. JAMA Psychiatry. 2016; 73(3): 211 - 20. doi: 10.1001/jamapsychiatry.2015.2313.

182. E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, Veijola J, Miettunen J. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013; 39(6): 1296 - 306. doi: 10.1093/schbul/sbs130.

183. Matar HE, Almerie MQ, Makhoul S et al. Pericyazine for schizophrenia. Cochrane Database Syst Rev 2014; 5: CD007479

184. Lamberti M. et al. Aripiprazole-induced tardive dyskinesia in 13 years old girl successfully treated with biperiden: A case report//Clinical Psychopharmacology and Neuroscience. - 2017. - Т. 15. - N. 3. - С. 285.

185. Pringsheim T. et al. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth//Paediatrics & child health. - 2011. - Т. 16. - N. 9. - С. 590 - 598.

186. Putignano D. et al. The evidence-based choice for antipsychotics in children and adolescents should be guaranteed//European journal of clinical pharmacology. - 2019. - С. 1 - 8.